Rucaparib As Maintenance Therapy Delays Progression in Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Niraparib plus Bevacizumab Combination Leads to Improved PFS Without Cumulative Toxicity in Advanced Ovarian Cancer
Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer
PARP Inhibitors in Ovarian Cancer: Choice May Depend on Treatment Setting, Mutation Status, and Side-Effect Profile
Time to First Subsequent Therapy Longer in Patients with Advanced Ovarian Cancer Who Are Treated with Niraparib
The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients.
Improvement in progression-free survival observed in the PRIMA clinical trial results in FDA approval of an additional indication for niraparib as first-line maintenance treatment of all patients with advanced ovarian cancer whose disease has had a complete or partial response to first-line platinum-based chemotherapy.
In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies.
The Centers for Medicare & Medicaid Services (CMS) has announced an expansion of coverage for telehealth services for Medicare beneficiaries. To qualify, 2-way real-time interactive communication between providers and patients using both audio and video technology is required.
According to data from the National Cancer Institute, approximately 1.2% of women in the United States will be diagnosed with ovarian cancer at some point in their lifetime. It is estimated that more than 20,000 women will be diagnosed with ovarian cancer in 2020, and nearly 14,000 women will die from the disease in the same year. Most deaths will occur in women aged >55 years.
Page 1 of 4
Results 1 - 10 of 37
Results 1 - 10 of 37